34 / 61
OAK: OS by histology
Histology information from eCRF
*Unstratified HRs;
§
P
values for descriptive purpose only
Barlesi, et al. ESMO 2016 (Abs. LBA44)
OS in squamous
OS in non-squamous
0
1.0
0.8
0.6
0.4
0.2
0
1.0
0.8
0.6
0.4
0.2
0
0
6
27
12
24
18
3
9
15
21
Time (months)
Time (months)
OS estimate
6
27
12
24
18
3
9
15
21
7.7
8.9
11.2
15.6
HR=0.73*
(95% CI 0.54–0.98)
p=0.0383
§
Atezolizumab (n=112)
Docetaxel (n=110)
HR=0.73*
(95% CI 0.60–0.89)
p=0.0015
§
Atezolizumab (n=313)
Docetaxel (n=315)
Minimum follow-up 19 months